$Uso del rituximab(anticuerpo monoclonal anti-CD20) en lupus eritematoso sistémico refractario a tratamiento: Caso clínico$
Código QR

Uso del rituximab(anticuerpo monoclonal anti-CD20) en lupus eritematoso sistémico refractario a tratamiento: Caso clínico

New therapeutic approaches that include depletion of B cells using rituximab, a chimeric monoclonal antibody directed against the B cell specific antigen CD-20 have been developed for the treatment of systemic lupus erythematosus (SLE). We report the case of a 18 years old girl with SLE that did not...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sabugo S,Francisca, Llanos M,Carolina, Soto S,Lilian, Gutiérrez,Jorge, Cuchacovich T,Miguel
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2005
Materias:	Lupus erythematosus, systemic Monoclonal antibody CD20 Rituximab
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872005000600010
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872005000600010
record_format	dspace
spelling	oai:scielo:S0034-988720050006000102005-08-26Uso del rituximab(anticuerpo monoclonal anti-CD20) en lupus eritematoso sistémico refractario a tratamiento: Caso clínicoSabugo S,FranciscaLlanos M,CarolinaSoto S,LilianGutiérrez,JorgeCuchacovich T,Miguel Lupus erythematosus, systemic Monoclonal antibody CD20 Rituximab New therapeutic approaches that include depletion of B cells using rituximab, a chimeric monoclonal antibody directed against the B cell specific antigen CD-20 have been developed for the treatment of systemic lupus erythematosus (SLE). We report the case of a 18 years old girl with SLE that did not respond and experienced adverse effects with the use of hydroxycloroquine, methotrexate, mycophenolate mofetil, azathioprine and high-dose steroids. Rituximab was given weekly at 375 mg/m² for four doses. The drug was well tolerated and the patient had no adverse reactions. She remains asymptomatic three months laterinfo:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.133 n.6 20052005-06-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872005000600010es10.4067/S0034-98872005000600010
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Lupus erythematosus, systemic Monoclonal antibody CD20 Rituximab
spellingShingle	Lupus erythematosus, systemic Monoclonal antibody CD20 Rituximab Sabugo S,Francisca Llanos M,Carolina Soto S,Lilian Gutiérrez,Jorge Cuchacovich T,Miguel Uso del rituximab(anticuerpo monoclonal anti-CD20) en lupus eritematoso sistémico refractario a tratamiento: Caso clínico
description	New therapeutic approaches that include depletion of B cells using rituximab, a chimeric monoclonal antibody directed against the B cell specific antigen CD-20 have been developed for the treatment of systemic lupus erythematosus (SLE). We report the case of a 18 years old girl with SLE that did not respond and experienced adverse effects with the use of hydroxycloroquine, methotrexate, mycophenolate mofetil, azathioprine and high-dose steroids. Rituximab was given weekly at 375 mg/m² for four doses. The drug was well tolerated and the patient had no adverse reactions. She remains asymptomatic three months later
author	Sabugo S,Francisca Llanos M,Carolina Soto S,Lilian Gutiérrez,Jorge Cuchacovich T,Miguel
author_facet	Sabugo S,Francisca Llanos M,Carolina Soto S,Lilian Gutiérrez,Jorge Cuchacovich T,Miguel
author_sort	Sabugo S,Francisca
title	Uso del rituximab(anticuerpo monoclonal anti-CD20) en lupus eritematoso sistémico refractario a tratamiento: Caso clínico
title_short	Uso del rituximab(anticuerpo monoclonal anti-CD20) en lupus eritematoso sistémico refractario a tratamiento: Caso clínico
title_full	Uso del rituximab(anticuerpo monoclonal anti-CD20) en lupus eritematoso sistémico refractario a tratamiento: Caso clínico
title_fullStr	Uso del rituximab(anticuerpo monoclonal anti-CD20) en lupus eritematoso sistémico refractario a tratamiento: Caso clínico
title_full_unstemmed	Uso del rituximab(anticuerpo monoclonal anti-CD20) en lupus eritematoso sistémico refractario a tratamiento: Caso clínico
title_sort	uso del rituximab(anticuerpo monoclonal anti-cd20) en lupus eritematoso sistémico refractario a tratamiento: caso clínico
publisher	Sociedad Médica de Santiago
publishDate	2005
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872005000600010
work_keys_str_mv	AT sabugosfrancisca usodelrituximabanticuerpomonoclonalanticd20enlupuseritematososistemicorefractarioatratamientocasoclinico AT llanosmcarolina usodelrituximabanticuerpomonoclonalanticd20enlupuseritematososistemicorefractarioatratamientocasoclinico AT sotoslilian usodelrituximabanticuerpomonoclonalanticd20enlupuseritematososistemicorefractarioatratamientocasoclinico AT gutierrezjorge usodelrituximabanticuerpomonoclonalanticd20enlupuseritematososistemicorefractarioatratamientocasoclinico AT cuchacovichtmiguel usodelrituximabanticuerpomonoclonalanticd20enlupuseritematososistemicorefractarioatratamientocasoclinico
_version_	1718436209958584320

Uso del rituximab(anticuerpo monoclonal anti-CD20) en lupus eritematoso sistémico refractario a tratamiento: Caso clínico

Ejemplares similares